Sarepta Therapeutics, Inc.
SRPT
$20.22
$0.160.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.48B | 2.23B | 1.90B | 1.64B | 1.50B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.48B | 2.23B | 1.90B | 1.64B | 1.50B |
| Cost of Revenue | 1.92B | 1.78B | 1.12B | 1.03B | 946.21M |
| Gross Profit | 565.14M | 449.69M | 778.36M | 609.29M | 558.78M |
| SG&A Expenses | 563.60M | 564.50M | 557.87M | 525.70M | 518.39M |
| Depreciation & Amortization | 2.47M | 2.41M | 2.41M | 2.57M | 2.40M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.48B | 2.35B | 1.68B | 1.56B | 1.47B |
| Operating Income | -932.00K | -117.21M | 218.08M | 81.03M | 37.99M |
| Income Before Tax | -24.13M | -164.19M | 260.77M | 129.40M | 62.22M |
| Income Tax Expenses | 33.83M | 84.20M | 25.54M | 7.56M | 14.93M |
| Earnings from Continuing Operations | -57.96 | -248.39 | 235.24 | 121.85 | 47.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.96M | -248.39M | 235.24M | 121.85M | 47.30M |
| EBIT | -932.00K | -117.21M | 218.08M | 81.03M | 37.99M |
| EBITDA | 40.15M | -78.25M | 255.81M | 119.67M | 77.75M |
| EPS Basic | -0.58 | -2.52 | 2.46 | 1.29 | 0.48 |
| Normalized Basic EPS | 0.05 | -0.67 | 1.48 | 0.60 | 0.35 |
| EPS Diluted | -0.76 | -2.58 | 2.39 | 1.24 | 0.44 |
| Normalized Diluted EPS | -0.14 | -0.80 | 1.34 | 0.58 | 0.32 |
| Average Basic Shares Outstanding | 387.04M | 383.65M | 380.28M | 377.62M | 371.12M |
| Average Diluted Shares Outstanding | 412.91M | 405.43M | 407.18M | 395.84M | 384.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |